nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-193-9-60-72nogr-1737Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYЭрадикационная терапия хеликобактериоза при помощи пробиотиков: проблемы и перспективыEradication therapy of helicobacteriosis with probiotics, problems, and prospectshttps://orcid.org/0000-0002-2569-6660ЕрмоленкоЕ. И.ErmolenkoE. I.

Ермоленко Елена Игоревна – доктор медицинских наук, заведующий лабораторией биомедицинской микроэкологии, отдел молекулярной микробиологии.

197376, Санкт- Петербург, ул. Академика Павлова, д. 12

Elena I. Ermolenko - PhD, MD (Medicine), Head, Laboratory of Biomedical Microecology; Professor, Faculty of Medical microbiology, Department of Medical Microbiology, , ResearcherID: E-1420–2014, Scopus Author ID: 13004322500.

12, Academic Pavlov street, Saint- Petersburg, 197376r

lermolenko1@yandex.ruhttps://orcid.org/0000-0002-7925-7743МолостоваА. С.MolostovaA. S.

Молостова Анастасия Сергеевна - врач-гастроэнтеролог.

197376, Санкт- Петербург, ул. Академика Павлова, д. 12

Anastasiia S. Molostova – Gastroenterologist.

12, Academic Pavlov street, Saint- Petersburg, 197376r

https://orcid.org/0000-0003-2732-5676ГладышевН. С.GladyshevN. S.

Гладышев Никита Сергеевич - научный сотрудник, лаборатория идентификации патогенов; студент образовательной программы «Лечебное дело», медицинского факультета.

197101, ул. Мира, д. 14, Санкт- Петербург; 199034, Санкт- Петербург, Университетская наб., д. 7–9

Nikita S. Gladyshev - Research Associate, Laboratory of Pathogen Identifi cation; student of the educational program “General Medicine”, Faculty of Medicine.

14, str. Mira, 197101, Saint- Petersburg; 7–9 Universitetskaya Emb., St Petersburg 199034

ФГБНУ Институт экспериментальной медициныРоссияInstitute of Experimental MedicineRussian FederationНаучно-исследовательский институт эпидемиологии и микробиологии имени Пастера; Санкт-Петербургский государственный университетРоссияSaint Petersburg Pasteur Institute; Saint Petersburg State UniversityRussian Federation202110122021096072Copyright © Ермоленко Е.И., Молостова А.С., Гладышев Н.С., 20212021Ермоленко Е.И., Молостова А.С., Гладышев Н.С.Ermolenko E.I., Molostova A.S., Gladyshev N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1737

В настоящее время остро стоит вопрос оптимизации терапии заболеваний желудка, ассоциированных с Helicobacter pylori, в связи с нарастанием устойчивости возбудителя к антибиотикам и наличия побочных эффектов стандартной терапии. Для ее оптимизации предлагается использование пробиотиков в качестве дополнения к стандартным схемам лечения или в качестве монотерапии. В обзоре приведены результаты исследований антихеликобактерной активности в системах in vitro и in vivo, а также оценка клинической эффективности различных пробиотических штаммов микроорганизмов при эрадикационной терапии. Рассмотрены некоторые механизмы действия пробиотиков при терапии заболеваний, ассоциированных с HP. Указаны проблемы и перспективы использования персонифицированной терапии хеликобактериоза пробиотиками и аутопробиотиками на основе штаммов, полученных из желудочно-кишечного тракта.

Currently, there is an urgent question of optimizing the treatment of stomach diseases associated with Helicobacter pylori, due to the increasing resistance of the pathogen to antibiotics and the presence of side effects of standard therapy. To optimize it, it is proposed to use probiotics as an additional or monotherapy. The review presents the results of studies of anti-helicobacter activity by in vitro and in vivo systems, as well as an assessment of the clinical effectiveness of various probiotic strains of microorganisms in eradication therapy. Several mechanisms of action of probiotics in the treatment of HP-related diseases are discussed. The problems and prospects of using personalized therapy of helicobacteriosis with probiotics and autoprobiotics, based on strains obtained from the gastrointestinal tract, are indicated.

Helicobacter pyloriLactobacillus spp.Enterococcus sp.Saccharomyces boulardiiпробиотикиаутопробиотикиHelicobacter pyloriLactobacillus spp.Enterococcus sp.Saccharomyces boulardiiprobioticsautoprobioticsReferencesMezmale L., Coelho L. G., Bordin D., Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020;25(S1):6-10. doi: 10.1111/hel.12734Mezmale L., Coelho L. G., Bordin D., Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020;25(S1):6-10. doi: 10.1111/hel.12734Zamani M., Ebrahimtabar F., Zamani V., et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-76. doi: 10.1111/apt.14561Zamani M., Ebrahimtabar F., Zamani V., et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-76. doi: 10.1111/apt.14561Гладышев Н.С., Молостова А. С., Сварваль А. В., и соавт. Желудочные и внежелудочные заболевания, связанные с инфекцией Helicobacter pylori. Здоровье - основа человеческого потенциала. 2019;1(6):14.Gladyshev N.S., Molostova A. S., Svarval A. V., et al. Gastric and extragastric diseases associated with Helicobacter pylori infection. Health-the base of human potential: problems and ways to solve them. 2019;1(6):14. (in Russ.)Чернин В.В., Бондаренко В. М., Червинец В. М., и соавт. Helicobacter pylori как составная часть микробиоценоза мукозной микрофлоры эзофагогастродуоденальной зоны в норме и патологии. Экспериментальная и клиническая гастроэнтерология. 2001; (8):66-72.Chernin V.V., Bondarenko V. M., Chervinets V. M., et al. [Helicobacter pylori as an integral part of the microbiocenosis of the mucous microflora of the esophagogastroduodenal zone in health and disease]. Eksp Klin Gastroenterol. 2001; (8):66-72. (in Russ.)Tsimmerman Ya. S. Has the discovery of Helicobacter pylori actually made a revolution in gastroenterology?. Klinicheskaya Meditsina. 2013;91(8):13-21. (in Russ.)@@ Циммерман Я. С. Действительно ли «Открытие» Helicobacter pylori стало «Революцией в гастроэнтерологии». Клиническая Медицина. 2013;91(8):13-21.Tsimmerman Ya. S. Has the discovery of Helicobacter pylori actually made a revolution in gastroenterology?. Klinicheskaya Meditsina. 2013;91(8):13-21. (in Russ.)Goh K.L., Chan W. K., Shiota S., Yamaoka Y. Epidemiology of Helicobacter pylori Infection and Public Health Implications. Helicobacter. 2011;16(S1):1-9. doi: 10.1111/j.1523-5378.2011.00874.xGoh K.L., Chan W. K., Shiota S., Yamaoka Y. Epidemiology of Helicobacter pylori Infection and Public Health Implications. Helicobacter. 2011;16(S1):1-9. doi: 10.1111/j.1523-5378.2011.00874.xИвашкин В.Т., Маев И. В., Лапина Т. Л., и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнад гастроэнтерологии, гепатологии, колопроктологии. 2018;28(3):107-11.Ivashkin V.T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288Лабезник Л.Б., Ткаченко Р. А., Обдулхаков Р. А., и соавт. Стандарты диагностики и лечения кислотозависимых и ассоциированных с Helicobacter pylori заболеваний. Экспериментальная и клиническая гастроэнтерология. 2013;(5):3-11.Lazebnik L.B., Tkachenko E. I., Abdulkhakov R. A., et al. [Standards for diagnosis and treatment of acid and Helicobacter pylori-associated diseases]. Eksp Klin Gastroenterol. 2013;(5):3-11. Russian. PMID: 24501939.Savoldi A., Carrara E., Graham D. Y., et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology [Internet]. 2018;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007Savoldi A., Carrara E., Graham D. Y., et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology [Internet]. 2018;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007Yang X., Wang J. X., Han S. X., Gao C. P. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Med (United States). 2019;98(7):1-7. doi: 10.1097/MD.0000000000014396Yang X., Wang J. X., Han S. X., Gao C. P. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Med (United States). 2019;98(7):1-7. doi: 10.1097/MD.0000000000014396Kostrzewska M., Świdnicka-Siergiejko A., Olszańska D., et al. The effect of omeprazole treatment on the gut microflora and neutrophil function. Clin Res Hepatol Gastroenterol. 2017;41(5):575-84. doi: 10.1016/j.clinre.2017.01.004Kostrzewska M., Świdnicka-Siergiejko A., Olszańska D., et al. The effect of omeprazole treatment on the gut microflora and neutrophil function. Clin Res Hepatol Gastroenterol. 2017;41(5):575-84. doi: 10.1016/j.clinre.2017.01.004Nagai S., Mimuro H., Yamada T., et al. Role of Peyer’s patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A. 2007;104(21):8971-6. doi: 10.1073/pnas.0609014104Nagai S., Mimuro H., Yamada T., et al. Role of Peyer’s patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci U S A. 2007;104(21):8971-6. doi: 10.1073/pnas.0609014104Suzuki H., Nishizawa T., Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010;5(4):649-648. doi: 10.2217/FMB.10.25Suzuki H., Nishizawa T., Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010;5(4):649-648. doi: 10.2217/FMB.10.25Aiba Y., Nakano Y., Koga Y., et al. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen. 2015;4(3):465-74. doi: 10.1002/mbo3.252Aiba Y., Nakano Y., Koga Y., et al. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen. 2015;4(3):465-74. doi: 10.1002/mbo3.252Rokka S., Pihlanto A., Korhonen H., Joutsjoki V. In vitro growth inhibition of Helicobacter pylori by lactobacilli belonging to the Lactobacillus plantarum group. Lett Appl Microbiol. 2006;43(5):508-13. doi: 10.1111/j.1472-765X.2006.01998.xRokka S., Pihlanto A., Korhonen H., Joutsjoki V. In vitro growth inhibition of Helicobacter pylori by lactobacilli belonging to the Lactobacillus plantarum group. Lett Appl Microbiol. 2006;43(5):508-13. doi: 10.1111/j.1472-765X.2006.01998.xSong H., Zhou L., Liu D., et al. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med. 2019;1551-62. doi: 10.3892/etm.2019.7742Song H., Zhou L., Liu D., et al. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med. 2019;1551-62. doi: 10.3892/etm.2019.7742Baryshnikova N., Ermolenko E., Svarval A., et al. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro. Int J Clin Med Microbiol Res Artic Open. 2017;1(123):1-4. doi: 10.15344/2456-4028/2017/123Baryshnikova N., Ermolenko E., Svarval A., et al. Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro. Int J Clin Med Microbiol Res Artic Open. 2017;1(123):1-4. doi: 10.15344/2456-4028/2017/123López-Brea M., Alarcón T., Domingo D., Díaz-Regañón J. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates. J Antimicrob Chemother. 2008;61(1):139-42. doi: 10.1093/jac/dkm404López-Brea M., Alarcón T., Domingo D., Díaz-Regañón J. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates. J Antimicrob Chemother. 2008;61(1):139-42. doi: 10.1093/jac/dkm404Midolo P.D., Lambert J. R., Hull R., et al. In vitro inhibition of HeIicobacterpyIori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;(79):475-9. doi: 10.1111/j.1365-2672.1995.tb03164.xMidolo P.D., Lambert J. R., Hull R., et al. In vitro inhibition of HeIicobacterpyIori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;(79):475-9. doi: 10.1111/j.1365-2672.1995.tb03164.xAiba Y., Suzuki N., Kabir A. M.A., et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93(11):2097-101. doi: 10.1016/S0002-9270(98)00481-XAiba Y., Suzuki N., Kabir A. M.A., et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol. 1998;93(11):2097-101. doi: 10.1016/S0002-9270(98)00481-XLorca G.L., Wadström T., Font de Valdez G., Ljungh Å. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39-44. doi: 10.1007/s002840010175Lorca G.L., Wadström T., Font de Valdez G., Ljungh Å. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39-44. doi: 10.1007/s002840010175Pinchuk I. V., Bressollier P., Verneuil B., et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156-61. doi: 10.1128/AAC.45.11.3156-3161.2001Pinchuk I. V., Bressollier P., Verneuil B., et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother. 2001;45(11):3156-61. doi: 10.1128/AAC.45.11.3156-3161.2001Nam H., Ha M., Lee E., Lee Y. Effect of Weissella confusa Strain PL9001 on the Adherence and Growth. Appl Environ Microbiol. 2002;68(9):4642-4645. doi: 10.1128/AEM.68.9.4642-4645.2002Nam H., Ha M., Lee E., Lee Y. Effect of Weissella confusa Strain PL9001 on the Adherence and Growth. Appl Environ Microbiol. 2002;68(9):4642-4645. doi: 10.1128/AEM.68.9.4642-4645.2002Mukai T., Asasaka T., Sato E., et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105-10. doi: 10.1111/j.1574-695X.2002.tb00541.xMukai T., Asasaka T., Sato E., et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105-10. doi: 10.1111/j.1574-695X.2002.tb00541.xCats A., Kuipers E. J., Bosschaert M. A.R., et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003;17(3):429-35. doi: 10.1046/j.1365-2036.2003.01452.xCats A., Kuipers E. J., Bosschaert M. A.R., et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003;17(3):429-35. doi: 10.1046/j.1365-2036.2003.01452.xSgouras D., Maragkoudakis P., Petraki K., et al. In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota. Appl Environ Microbiol. 2004;70(1):518-26. doi: 10.1128/AEM.70.1.518-526.2004Sgouras D., Maragkoudakis P., Petraki K., et al. In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota. Appl Environ Microbiol. 2004;70(1):518-26. doi: 10.1128/AEM.70.1.518-526.2004Enany S., Abdalla S. In vitro antagonistic activity of lactobacillus casei against Helicobacter pylori. Brazilian J Microbiol. 2015;46(4):1201-6. doi: 10.1590/S1517-838246420140675Enany S., Abdalla S. In vitro antagonistic activity of lactobacillus casei against Helicobacter pylori. Brazilian J Microbiol. 2015;46(4):1201-6. doi: 10.1590/S1517-838246420140675Ushiyama A., Tanaka K., Aiba Y., et al. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18(8):986-91. doi: 10.1046/j.1440-1746.2003.03102.xUshiyama A., Tanaka K., Aiba Y., et al. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18(8):986-91. doi: 10.1046/j.1440-1746.2003.03102.xKaur B., Garg N., Sachdev A., Kumar B. Effect of the oral intake of probiotic pediococcus acidilactici BA28 on Helicobacter pylori causing peptic ulcer in C57BL/6 mice models. Appl Biochem Biotechnol. 2014;172(2):973-83. doi: 10.1007/s12010-013-0585-4Kaur B., Garg N., Sachdev A., Kumar B. Effect of the oral intake of probiotic pediococcus acidilactici BA28 on Helicobacter pylori causing peptic ulcer in C57BL/6 mice models. Appl Biochem Biotechnol. 2014;172(2):973-83. doi: 10.1007/s12010-013-0585-4Holz C., Busjahn A., Mehling H., et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins [Internet]. 2015;7(2):91-100. doi: 10.1007/s12602-014-9181-3Holz C., Busjahn A., Mehling H., et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins [Internet]. 2015;7(2):91-100. doi: 10.1007/s12602-014-9181-3Sakarya S., Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122(10):941-50. doi: 10.1111/apm.12237Sakarya S., Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122(10):941-50. doi: 10.1111/apm.12237Boyanova L., Gergova G., Markovska R., et al. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65(6):469-74. doi: 10.1111/lam.12807Boyanova L., Gergova G., Markovska R., et al. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65(6):469-74. doi: 10.1111/lam.12807de Korwin J. D., Ianiro G., Gibiino G., Gasbarrini A. Helicobacter pylori infection and extragastric diseases in 2017. Helicobacter. 2017;22:1-8. doi: 10.1111/hel.12411de Korwin J. D., Ianiro G., Gibiino G., Gasbarrini A. Helicobacter pylori infection and extragastric diseases in 2017. Helicobacter. 2017;22:1-8. doi: 10.1111/hel.12411Rezaee P., Kermanshahi R. K., Falsafi T. Antibacterial activity of lactobacilli probiotics on clinical strains of Helicobacter pylori. Iran J Basic Med Sci. 2019;22(10):1118-24. doi: 10.22038/ijbms.2019.33321.7953Rezaee P., Kermanshahi R. K., Falsafi T. Antibacterial activity of lactobacilli probiotics on clinical strains of Helicobacter pylori. Iran J Basic Med Sci. 2019;22(10):1118-24. doi: 10.22038/ijbms.2019.33321.7953Chen X., Liu X. M., Tian F., et al. Antagonistic activities of Lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci. 2012;77(1). doi: 10.1111/j.1750-3841.2011.02498.xChen X., Liu X. M., Tian F., et al. Antagonistic activities of Lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci. 2012;77(1). doi: 10.1111/j.1750-3841.2011.02498.xSaracino I.M., Pavoni M., Saccomanno L., et al. Antimicrobial efficacy of five probiotic strains against Helicobacter pylori. Antibiotics. 2020;9(5):1-10. doi: 10.3390/antibiotics9050244Saracino I.M., Pavoni M., Saccomanno L., et al. Antimicrobial efficacy of five probiotic strains against Helicobacter pylori. Antibiotics. 2020;9(5):1-10. doi: 10.3390/antibiotics9050244Coconnier M.H., Lievin V., Hemery E., Servin A. L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998;64(11):4573-80. doi: 10.1128/AEM.64.11.4573-4580.1998Coconnier M.H., Lievin V., Hemery E., Servin A. L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998;64(11):4573-80. doi: 10.1128/AEM.64.11.4573-4580.1998Suvorov A., Karaseva A., Kotyleva M., et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front Microbiol. 2018;9(SEP):1-9. doi: 10.3389/fmicb.2018.01869Suvorov A., Karaseva A., Kotyleva M., et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front Microbiol. 2018;9(SEP):1-9. doi: 10.3389/fmicb.2018.01869Ермоленко Е.И., Ждан-Пушкина С.Х., Суворов А. Н. Взаимодействие Candida albicans и Lactobacillus plantarum in vitro. Экспериментальная микология. 2004;49-54.Ermolenko E.I., Zhdan-Pushkina S. Kh., Suvorov A. N. In vitro interaction between candida albicans and l actobacillus plantarum. Eksperimentalnaya mikologiya. 2004;6(2):49-54. (in Russ.)Takahashi M., Taguchi H., Yamaguchi H., et al. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol. 2000;49(7):635-42. doi: 10.1099/0022-1317-49-7-635Takahashi M., Taguchi H., Yamaguchi H., et al. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol. 2000;49(7):635-42. doi: 10.1099/0022-1317-49-7-635Poppi L.B., Rivaldi J. D., Coutinho T. S., et al. Effect of Lactobacillus sp. isolates supernatant on Escherichia coli O157: H7 enhances the role of organic acids production as a factor for pathogen control. Pesqui Vet Bras. 2015;35(4):353-9. doi: 10.1590/S0100-736X2015000400007Poppi L.B., Rivaldi J. D., Coutinho T. S., et al. Effect of Lactobacillus sp. isolates supernatant on Escherichia coli O157: H7 enhances the role of organic acids production as a factor for pathogen control. Pesqui Vet Bras. 2015;35(4):353-9. doi: 10.1590/S0100-736X2015000400007Batdorj B., Trinetta V., Dalgalarrondo M., et al. Isolation, taxonomic identification and hydrogen peroxide production by Lactobacillus delbrueckii subsp. lactis T31, isolated from Mongolian yoghurt: Inhibitory activity on food-borne pathogens. J Appl Microbiol. 2007;103(3):584-93. doi: 10.1111/j.1365-2672.2007.03279.xBatdorj B., Trinetta V., Dalgalarrondo M., et al. Isolation, taxonomic identification and hydrogen peroxide production by Lactobacillus delbrueckii subsp. lactis T31, isolated from Mongolian yoghurt: Inhibitory activity on food-borne pathogens. J Appl Microbiol. 2007;103(3):584-93. doi: 10.1111/j.1365-2672.2007.03279.xNeshani A., Zare H., Akbari Eidgahi M. R., et al. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019;24(1). doi: 10.1111/hel.12555Neshani A., Zare H., Akbari Eidgahi M. R., et al. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019;24(1). doi: 10.1111/hel.12555Tsai C.C., Huang L. F., Lin C. C., Tsen H. Y. Antagonistic activity against Helicobacter pylori infection in vitro by a strain of Enterococcus faecium TM39. Int J Food Microbiol. 2004;96(1):1-12. doi: 10.1016/j.ijfoodmicro.2003.10.019Tsai C.C., Huang L. F., Lin C. C., Tsen H. Y. Antagonistic activity against Helicobacter pylori infection in vitro by a strain of Enterococcus faecium TM39. Int J Food Microbiol. 2004;96(1):1-12. doi: 10.1016/j.ijfoodmicro.2003.10.019Chenoll E., Casinos B., Bataller E., et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77(4):1335-43. doi: 10.1128/AEM.01820-10Chenoll E., Casinos B., Bataller E., et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77(4):1335-43. doi: 10.1128/AEM.01820-10Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A. L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3):1-7. doi: 10.1093/jn/137.3.812SLesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A. L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3):1-7. doi: 10.1093/jn/137.3.812SKim J.E., Kim M. S., Yoon Y. S., et al. Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol. 2014;52(11):955-62. doi: 10.1007/s12275-014-4355-yKim J.E., Kim M. S., Yoon Y. S., et al. Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection. J Microbiol. 2014;52(11):955-62. doi: 10.1007/s12275-014-4355-yErmolenko E., Varsin S., Baryshnikova N., et al. Gastrointestinal Dysbiosis Accompanied of Helicobacter pylori Infection and its Correction by Probiotic. J Clin Gastroenterol Treat. 2018;4(1):1-6. doi: 10.23937/2469-584X/1510055Ermolenko E., Varsin S., Baryshnikova N., et al. Gastrointestinal Dysbiosis Accompanied of Helicobacter pylori Infection and its Correction by Probiotic. J Clin Gastroenterol Treat. 2018;4(1):1-6. doi: 10.23937/2469-584X/1510055Ермоленко Е. И. Бактериоцины Энтерококков: Проблемы И Перспективы Использования (Обзор Литературы). Вестник Санкт-Петербургского Университета Серия 11 Медицина. 2009;11(3):78-93.Ermolenko E.I. [Bacteriocins of enterococcus: problems and prospects uses (literature review)]. Vestnik of Saint Petersburg University. Medicine. 2009;11(3):78-93. (in Russ.)Kabir A.M.A., Aiba Y., Takagi A., et al. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut. 1997;41(1):49-55. doi: 10.1136/gut.41.1.49Kabir A.M.A., Aiba Y., Takagi A., et al. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut. 1997;41(1):49-55. doi: 10.1136/gut.41.1.49Myllyluoma E., Ahonen A. M., Korpela R., et al. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immunol. 2008;15(9):1472-82. doi: 10.1128/CVI.00080-08Myllyluoma E., Ahonen A. M., Korpela R., et al. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immunol. 2008;15(9):1472-82. doi: 10.1128/CVI.00080-08Salas-Jara M.J., Sanhueza E. A., Retamal-Díaz A., et al. Probiotic Lactobacillus fermentum UCO-979C biofilm formation on AGS and Caco-2 cells and Helicobacter pylori inhibition. Biofouling. 2016;32(10):1245-57. doi: 10.1080/08927014.2016.1249367Salas-Jara M.J., Sanhueza E. A., Retamal-Díaz A., et al. Probiotic Lactobacillus fermentum UCO-979C biofilm formation on AGS and Caco-2 cells and Helicobacter pylori inhibition. Biofouling. 2016;32(10):1245-57. doi: 10.1080/08927014.2016.1249367Ji J., Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21031136Ji J., Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int J Mol Sci. 2020;21(3). doi: 10.3390/ijms21031136Van Den Brink G. R., Tytgat K. M.A.J., Van Der Hulst R. W.M., et al. H pylori colocalises with MUC5AC in the human stomach. Gut. 2000;46(5):601-7. doi: 10.1136/gut.46.5.601Van Den Brink G. R., Tytgat K. M.A.J., Van Der Hulst R. W.M., et al. H pylori colocalises with MUC5AC in the human stomach. Gut. 2000;46(5):601-7. doi: 10.1136/gut.46.5.601Alvi S., Javeed A., Akhtar B., et al. Probiotics for cure of Helicobacter pylori infection: A review. Int J Food Prop. 2017;20(10):2215-22. doi: 10.1080/10942912.2016.1233432Alvi S., Javeed A., Akhtar B., et al. Probiotics for cure of Helicobacter pylori infection: A review. Int J Food Prop. 2017;20(10):2215-22. doi: 10.1080/10942912.2016.1233432Pan M., Wan C., Xie Q., et al. Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. J Dairy Sci. 2016;99(2):970-81. DOI:10.3168/jds.2015-10510Pan M., Wan C., Xie Q., et al. Changes in gastric microbiota induced by Helicobacter pylori infection and preventive effects of Lactobacillus plantarum ZDY 2013 against such infection. J Dairy Sci. 2016;99(2):970-81. DOI:10.3168/jds.2015-10510Asgari B., Kermanian F., Hedayat Yaghoobi M., et al. The Anti- Helicobacter pylori Effects of Lactobacillus acidophilus, L. plantarum, and L. rhamnosus in Stomach Tissue of C57BL/6 Mice. Visc Med. 2020;36(2):137-43. doi: 10.1159/000500616Asgari B., Kermanian F., Hedayat Yaghoobi M., et al. The Anti- Helicobacter pylori Effects of Lactobacillus acidophilus, L. plantarum, and L. rhamnosus in Stomach Tissue of C57BL/6 Mice. Visc Med. 2020;36(2):137-43. doi: 10.1159/000500616Zhang M., Zhang C., Zhao J., et al. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog. 2020;147(March):104403. doi: 10.1016/j.micpath.2020.104403Zhang M., Zhang C., Zhao J., et al. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog. 2020;147(March):104403. doi: 10.1016/j.micpath.2020.104403Chen Y.-H., Tsai W.-H., Wu H.-Y., et al. Probiotic LactoBacillus spp. act Against Helicobacter pylori-induced Inflammation. J Clin Med. 2019;8(1):90. doi: 10.3920/BM2017.0160Chen Y.-H., Tsai W.-H., Wu H.-Y., et al. Probiotic LactoBacillus spp. act Against Helicobacter pylori-induced Inflammation. J Clin Med. 2019;8(1):90. doi: 10.3920/BM2017.0160Merino J.S., García A., Pastene E., et al. Lactobacillus fermentum UCO-979C strongly inhibited Helicobacter pylori SS1 in Meriones unguiculatus. Benef Microbes. 2018;9(4):625-7. doi: 10.3920/BM2017.0160Merino J.S., García A., Pastene E., et al. Lactobacillus fermentum UCO-979C strongly inhibited Helicobacter pylori SS1 in Meriones unguiculatus. Benef Microbes. 2018;9(4):625-7. doi: 10.3920/BM2017.0160Sykora J., Valeckova K., Amlerova J., et al. Effects of a Specially Designed Fermented Milk Product Containing Probiotic Lactobacillus casei DN-114 001 and the Eradication of H. pylori in Children. J Clin Gastroenterol. 2005;39(8):692-8. doi: 10.1097/01.mcg.0000173855.77191.44Sykora J., Valeckova K., Amlerova J., et al. Effects of a Specially Designed Fermented Milk Product Containing Probiotic Lactobacillus casei DN-114 001 and the Eradication of H. pylori in Children. J Clin Gastroenterol. 2005;39(8):692-8. doi: 10.1097/01.mcg.0000173855.77191.44Ojetti V., Bruno G., Ainora M. E., et al. Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract. 2012;2012. doi: 10.1155/2012/740381Ojetti V., Bruno G., Ainora M. E., et al. Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract. 2012;2012. doi: 10.1155/2012/740381Felley C.P., Corthésy-Theulaz I., Rivero J. L.B., et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 2001;13(1):25-9. doi: 10.1097/00042737-200101000-00005Felley C.P., Corthésy-Theulaz I., Rivero J. L.B., et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 2001;13(1):25-9. doi: 10.1097/00042737-200101000-00005Francesco V.D., Stoppino V., Sgarro C., Faleo D. Lactubacillus aciduphilus administration to omeprazole / amoxycillin-based double in Helicobacter pykwi eradication added therapy. Dig Liver Dis. 2000;32(8):746-7. doi: 10.1016/s1590-8658(00)80343-6Francesco V.D., Stoppino V., Sgarro C., Faleo D. Lactubacillus aciduphilus administration to omeprazole / amoxycillin-based double in Helicobacter pykwi eradication added therapy. Dig Liver Dis. 2000;32(8):746-7. doi: 10.1016/s1590-8658(00)80343-6Du Y.Q., Su T., Fan J. G., et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012;18(43):6302-7. doi: 10.3748/wjg.v18.i43.6302Du Y.Q., Su T., Fan J. G., et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol. 2012;18(43):6302-7. doi: 10.3748/wjg.v18.i43.6302Cindoruk M., Erkan G., Karakan T., et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309-16. doi: 10.1111/j.1523-5378.2007.00516.xCindoruk M., Erkan G., Karakan T., et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309-16. doi: 10.1111/j.1523-5378.2007.00516.xHurduc V., Plesca D., Dragomir D., et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr Int J Paediatr. 2009;98(1):127-31. doi: 10.1111/j.1651-2227.2008.00977.xHurduc V., Plesca D., Dragomir D., et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr Int J Paediatr. 2009;98(1):127-31. doi: 10.1111/j.1651-2227.2008.00977.xCremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744-9. doi: 10.1016/S0002-9270(02)05480-1Cremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744-9. doi: 10.1016/S0002-9270(02)05480-1Song M.J., Park D. Il, Park J. H., et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.xSong M.J., Park D. Il, Park J. H., et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.xУспенский Ю.П., Барышникова Н. В. Оптимизация лечения заболеваний, ассоциированных с инфекцией Helicobacter pylori, с учетом современных рекомендаций. Актуальные вопросы оздоровления детей и подростков с помощью стационарзамещающих технологий. 2016;37-48.Uspenskiy Yu.P., Baryshnikova N. V. [Optimization of treatment of diseases associated with Helicobacter pylori infection, taking into account modern recommendations]. Aktualnyye voprosy ozdorovleniya detey i podrostkov s pomoshchyu statsionarzameshchayushchikh tekhnologiy. 2016;37-48. (in Russ.)Goldman C.G., Barrado D. A., Balcarce N., et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;22(10):984-8. doi: 10.1016/j.nut.2006.06.008Goldman C.G., Barrado D. A., Balcarce N., et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;22(10):984-8. doi: 10.1016/j.nut.2006.06.008Корниенко Е.А., Минина С. Н. Пробиотики в лечении инфекции Helicobacter pylori. Медицинский совет. 2015;(14):69-72.Kornienko E.A., Minina S. N. Probiotics in the treatment of Helicobacter pylori infection. Meditsinskiy sovet = Medical Council. 2015;(14):69-72. (In Russ.). doi: 10.21518/2079-701X-2015-14-69-72.@@ Корниенко Е.А., Минина С. Н. Пробиотики в лечении инфекции Helicobacter pylori. Медицинский совет. 2015;(14):69-72.Суворов А.Н., Барышникова Н. В., Сварваль А. В., Ниязов Р. М. Возможности некоторых пробиотических штаммов в эрадикации Helicobacter pylori in vitro и in vivo. Фарматека. 2018;(2):74-8.Suvorov A.N., Baryshnikova N. V., Svarval A. V., Niyazov R. M. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Pharmateca. 2018; (2): 74-8. doi: 10.18565/pharmateca.2018.2.74-78Armuzzi A., Cremonini F., Ojetti V., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: A pilot study. Digestion. 2001;63(1):1-7. doi: 10.1159/000051865Armuzzi A., Cremonini F., Ojetti V., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: A pilot study. Digestion. 2001;63(1):1-7. doi: 10.1159/000051865Szajewska H., Albrecht P., Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: Effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48(4):431-6. doi: 10.1097/MPG.0b013e318182e716Szajewska H., Albrecht P., Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: Effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48(4):431-6. doi: 10.1097/MPG.0b013e318182e716Sahagún-Flores J.E., López-Peña L.S., de la Cruz-Ramírez Jaimes J., et al. Eradication of Helicobacter pylori: triple treatment scheme plus Lactobacillus vs. triple treatment alone. Cir Cir. 2007 Sep-Oct;75(5):333-6. Spanish. PMID: 18158878.Sahagún-Flores J.E., López-Peña L.S., de la Cruz-Ramírez Jaimes J., et al. Eradication of Helicobacter pylori: triple treatment scheme plus Lactobacillus vs. triple treatment alone. Cir Cir. 2007 Sep-Oct;75(5):333-6. Spanish. PMID: 18158878.Lionetti E., Miniello V. L., Castellaneta S. P., et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24(10):1461-8. doi: 10.1111/j.1365-2036.2006.03145.xLionetti E., Miniello V. L., Castellaneta S. P., et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24(10):1461-8. doi: 10.1111/j.1365-2036.2006.03145.xDeguchi R., Nakaminami H., Rimbara E., et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol. 2012;27(5):888-92. doi: 10.1111/j.1440-1746.2011.06985.xDeguchi R., Nakaminami H., Rimbara E., et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol. 2012;27(5):888-92. doi: 10.1111/j.1440-1746.2011.06985.xNista E.C., Candelli M., Cremonini F., et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004;20(10):1181-8. doi: 10.1111/j.1365-2036.2004.02274.xNista E.C., Candelli M., Cremonini F., et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004;20(10):1181-8. doi: 10.1111/j.1365-2036.2004.02274.xDajani A.I., Abu Hammour A. M., Yang D. H., et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol. 2013;19(3):113-20. doi: 10.4103/1319-3767.111953.Dajani A.I., Abu Hammour A. M., Yang D. H., et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol. 2013;19(3):113-20. doi: 10.4103/1319-3767.111953.Myllyluoma E., Veijola L., Ahlroos T., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - A placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005;21(10):1263-72. doi: 10.1111/j.1365-2036.2005.02448.x.Myllyluoma E., Veijola L., Ahlroos T., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - A placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005;21(10):1263-72. doi: 10.1111/j.1365-2036.2005.02448.x.Boonyaritichaikij S., Kuwabara K., Nagano J., et al. Long-term Administration of Probiotics to Asymptomatic Pre-school Children for Either the Eradication or the Prevention of Helicobacter pylori Infection. Helicobacter. 2009;14(3):202-7. doi: 10.1111/j.1523-5378.2009.00675.x.Boonyaritichaikij S., Kuwabara K., Nagano J., et al. Long-term Administration of Probiotics to Asymptomatic Pre-school Children for Either the Eradication or the Prevention of Helicobacter pylori Infection. Helicobacter. 2009;14(3):202-7. doi: 10.1111/j.1523-5378.2009.00675.x.Sakamoto I., Igarashi M., Kimura K., et al. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 2001;47(5):709-10. doi: 10.1093/jac/47.5.709Sakamoto I., Igarashi M., Kimura K., et al. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 2001;47(5):709-10. doi: 10.1093/jac/47.5.709Shimizu T., Haruna H., Hisada K., Yamashiro Y. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. J Antimicrob Chemother. 2002;50(4):617-8. doi: 10.1093/jac/dkf157.Shimizu T., Haruna H., Hisada K., Yamashiro Y. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. J Antimicrob Chemother. 2002;50(4):617-8. doi: 10.1093/jac/dkf157.Dore M.P., Cuccu M., Pes G. M., et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014;9(6):649-54. doi: 10.1007/s11739-013-1013-z.Dore M.P., Cuccu M., Pes G. M., et al. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014;9(6):649-54. doi: 10.1007/s11739-013-1013-z.Francavilla R., Lionetti E., Castellaneta S. P., et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study. Helicobacter. 2008;13(2):127-34. doi: 10.1111/j.1523-5378.2008.00593.x.Francavilla R., Lionetti E., Castellaneta S. P., et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study. Helicobacter. 2008;13(2):127-34. doi: 10.1111/j.1523-5378.2008.00593.x.Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr Int J Paediatr. 2005;94(12):1747-51. doi: 10.1111/j.1651-2227.2005.tb01848.x.Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr Int J Paediatr. 2005;94(12):1747-51. doi: 10.1111/j.1651-2227.2005.tb01848.x.Namkin K., Zardast M., Basirinejad F. Saccharomyces boulardii in Helicobacter pylori eradication in children: A randomized trial from Iran. Iran J Pediatr. 2016;26(1):1-5. doi: 10.5812/ijp.3768.Namkin K., Zardast M., Basirinejad F. Saccharomyces boulardii in Helicobacter pylori eradication in children: A randomized trial from Iran. Iran J Pediatr. 2016;26(1):1-5. doi: 10.5812/ijp.3768.Rosania R., Minenna M. F., Giorgio F., et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: A placebo-controlled pilot study. Inflamm Allergy - Drug Targets. 2012;11(3):244-9. doi: 10.2174/187152812800392698.Rosania R., Minenna M. F., Giorgio F., et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: A placebo-controlled pilot study. Inflamm Allergy - Drug Targets. 2012;11(3):244-9. doi: 10.2174/187152812800392698.Pantoflickova D., Dorta G., Ravic M., et al. Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507-14. doi: 10.1046/j.1365-2036.2003.01496.xPantoflickova D., Dorta G., Ravic M., et al. Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507-14. doi: 10.1046/j.1365-2036.2003.01496.xСиманенков В.И., Суворов А. Н., Захарова Л. Б., et al. Способ лечения хронического H.pylori-ассоциированного гастрита препаратом ламинолакт. 2005. p. 1-6.Simanenkov V.I., Suvorov A. N., Zakharova L. B., et al. Method for treatment of chronic Helicobacter pylori- associated gastritis with preparation “Laminolakt”. 2005. p. 1-6. (in Russ.)Торшин И.Ю., Громова О. А., Максимов В. А., Захарова И. Н., Малявская С. И. Анализ штамм-специфичных эффектов лактобацилл L. casei DG (L. paracasei CNCM I-1572) и возможность их применения в клинической практике. Экспериментальная и клиническая гастроэнтерология. 2019;(2):151-158Torshin Y., Gromova O. A., Maksimov V. A., et al. Analysis of the strain-specifi c eff ects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2):151-8. (in Russ.) doi: 10.31146/1682-8658-ecg-162-2-151-158.Tyagi A.K., Prasad S. Commentary: Probiotic and technological properties of LactoBacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2015;6(MAY):1-3. doi: 10.3389/fmicb.2015.00433.Tyagi A.K., Prasad S. Commentary: Probiotic and technological properties of LactoBacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2015;6(MAY):1-3. doi: 10.3389/fmicb.2015.00433.Ермоленко Е.И., Молостова А. С., Колобов А. Н., et al. Антагонистическая активность пробиотиков и бактериоцинов в отношении Helicobacter pylori. Гастроэнтерология Санкт-Петербурга. 2019; 2:18-18.1.Ermolenko E.I., Molostova A. S., Kolobov A. N., et al. [Antagonistic activity of probiotics and bacteriocins against Helicobacter pylori]. Gastroenterologiya Sankt-Peterburga. 2019; 2:18-18.1. (in Russ.)

The authors declare that there are no conflicts of interest present.